

Validation data for Anti-CoV2RBD-c1-hIgG1 (clone H4)

<https://www.invivogen.com/sars2-spike-h4-mab>

For research use only

Version 20130-ED

Anti-CoV2RBD-c1-hIgG1 is a recombinant monoclonal antibody (mAb) featuring the variable region of the SARS-CoV-2 spike mAb (clone H4), which specifically targets the SARS-CoV-2 Spike receptor-binding domain (RBD), and the constant region of the human IgG1 (hIgG1) isotype. The binding of the antibody has been validated by ELISA using a coated Spike-RBD-His fusion peptide (Figure 1), and with flow cytometry of HEK293 cells expressing the full length SARS-CoV-2 spike (S) protein (Figure 2).

Binding of Anti-CoV2RBD-c1-hIgG1 to SARS-CoV-2 spike RBD by ELISA




Figure 1: Validation of binding to SARS-CoV-2 RBD by ELISA. SARS-CoV-2 Spike-RBD-His fusion peptide (5 µg/ml) was coated onto ELISA plates overnight. A serial dilution of Anti-CoV2RBD-c1-hIgG1 (red curve) or Anti-βGal-hIgG1 (control antibody; grey curve) was added to the pre-coated plate and incubated for 1 hour. Subsequently, binding was detected with a HRP-labelled anti-hIgG1 antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride). Absorbance was read at 490 nm.

Binding of Anti-CoV2RBD-c1-hIgG1 to SARS-CoV-2 spike-expressing cells




Figure 2: Validation of binding to SARS-CoV-2 spike-expressing cells. HEK293 wild-type (WT) and HEK293-expressing SARS-CoV-2 spike (S) cells were incubated with Anti-CoV2RBD-c1-hIgG1 (Blue and Red curve) or with a negative control mAb (Anti-βgal-hIgG1; orange curve) for 1 hour at 4°C (10 µg/ml per 5 × 10⁵ cells). Following this, the cells were washed and incubated with an anti-human IgG-Fc PE-conjugated mAb for 1 hour at 4°C. The binding affinity was then measured using flow cytometry.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3-622-34-80
E-mail: info@invivogen.com